ClearLight Closes Lab Services and Offers Expert Consulting Services Learn More

ClearLight Diagnostics to Present at the 10th Annual Biotech Showcase™

Posted on Jan 03, 2018

SUNNYVALE, CA         January 3, 2018 (PR NEWSWIRE)

ClearLight Diagnostics, LLC (ClearLight), a developer of an automated, next generation tissue processing and 3D imaging platform, today announced that Sarah McCurdy, Chief Executive Officer, will present at the 10th Annual Biotech ShowcaseTM, taking place January 8 -10 at the Hilton San Francisco Union Square.

ClearLight is developing an automated research instrument platform based on the tissue lipid clearing method, CLARITY and associated imaging technologies that can identify and characterize the 3D spatial heterogeneity of the tumor microenvironment, including phenotypic immune infiltrates, in large tissue volumes. This non-destructive tissue analysis tool will advance tumor profiling and personalized medicine by elucidating important spatial relationships within the tumor microenvironment of patients with cancer.

Biotech ShowcaseTM 2018 – Presentation Timeslot Details

Date: Monday, January 8, 2018

Time: 8:30 AM

Track: Franciscan – D (Ballroom Level)

About ClearLight Diagnostics

Founded by Karl Deisseroth M.D., Ph.D., ClearLight is developing an integrated tissue processing instrumentation platform with the associated optimized biomarker panels based on the CLARITY lipid-clearing technique developed by Dr. Deisseroth and colleagues at Stanford University. This technique enables the transformation of tissue into a nanoporous, hydrogel-hybridized form that is crosslinked to a three-dimensional network of hydrophilic polymers. The process produces a fully assembled, intact tissue, which is permeable to macromolecules and optically transparent, thus allowing for robust three-dimensional imaging of subcellular components (DNA, RNA and protein) and heterogeneous cellular interactions within the tumor microenvironment.  This technology, paired with the development of a tissue imaging platform that includes the revolutionary microscopy method, COLM (CLARITY Optimized Light-sheet Microscopy) will enable unprecedented depth and acceleration of image collection from lipid-cleared samples interrogated with biomolecules.

Visit us at



Sarah McCurdy, CEO

(510) 470-5042




Analysis can be performed for select biomarkers, please contact us to find out if your target of interest is one of them. Imaging is currently performed on select fields of view instead of the entire sample.

Submission Guidelines

Tissue Sample Requirements: